- Home
- OPFI vs BWAY Comparison
OPFI vs BWAY Comparison
Compare OPFI & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- BWAY
- Stock Information
- Founded
- OPFI 2009
- BWAY 2003
- Country
- OPFI United States
- BWAY Israel
- Employees
- OPFI N/A
- BWAY N/A
- Industry
- OPFI Finance: Consumer Services
- BWAY Medical/Dental Instruments
- Sector
- OPFI Finance
- BWAY Health Care
- Exchange
- OPFI Nasdaq
- BWAY Nasdaq
- Market Cap
- OPFI 290.9M
- BWAY 177.4M
- IPO Year
- OPFI N/A
- BWAY 2019
- Fundamental
- Price
- OPFI $15.03
- BWAY $10.66
- Analyst Decision
- OPFI Buy
- BWAY Strong Buy
- Analyst Count
- OPFI 2
- BWAY 3
- Target Price
- OPFI $7.50
- BWAY $13.17
- AVG Volume (30 Days)
- OPFI 2.5M
- BWAY 57.5K
- Earning Date
- OPFI 03-06-2025
- BWAY 03-05-2025
- Dividend Yield
- OPFI 0.80%
- BWAY N/A
- EPS Growth
- OPFI 775.86
- BWAY N/A
- EPS
- OPFI 0.38
- BWAY 0.04
- Revenue
- OPFI $260,661,000.00
- BWAY $38,631,000.00
- Revenue This Year
- OPFI N/A
- BWAY $388.82
- Revenue Next Year
- OPFI $6.51
- BWAY $18.70
- P/E Ratio
- OPFI $39.68
- BWAY $128.37
- Revenue Growth
- OPFI 23.85
- BWAY 34.19
- 52 Week Low
- OPFI $2.35
- BWAY $4.61
- 52 Week High
- OPFI $15.13
- BWAY $11.25
- Technical
- Relative Strength Index (RSI)
- OPFI 76.48
- BWAY 46.35
- Support Level
- OPFI $11.21
- BWAY $10.24
- Resistance Level
- OPFI $14.85
- BWAY $10.89
- Average True Range (ATR)
- OPFI 1.17
- BWAY 0.47
- MACD
- OPFI 0.17
- BWAY -0.04
- Stochastic Oscillator
- OPFI 77.48
- BWAY 10.34
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.